- The study addressed whether adding dexamethasone to bupivacaine offers a cost-effective alternative to liposomal bupivacaine for TAP blocks in DIEP flap patients.
- This retrospective single-institution study included 178 patients undergoing DIEP flap breast reconstruction between 2018 and 2023.
- Patients receiving bupivacaine with dexamethasone had a shorter LOS (2.88 vs 3.49 days; p<0.001) and lower MME usage (70.6 vs 104.7; p<0.001).
- The authors concluded that bupivacaine with dexamethasone is a clinically effective and cost-effective alternative for post-operative pain management.
- This suggests that adding dexamethasone to bupivacaine could optimize pain control and resource utilization in DIEP flap reconstruction.
Optimizing Postoperative Pain Control in Autologous Breast Reconstruction
Autologous breast reconstruction using a deep inferior epigastric perforator (DIEP) flap is a preferred technique following mastectomy, but managing donor-site pain from the abdominal harvest is a significant clinical challenge that can prolong recovery and opioid use [1, 2]. Transversus abdominis plane (TAP) blocks are a cornerstone of enhanced recovery protocols for this and other abdominal surgeries, proven to reduce postoperative pain and opioid requirements [3, 4, 5]. A persistent clinical question, however, involves the choice of anesthetic. While extended-release liposomal bupivacaine is available, its high cost and debated superiority over standard bupivacaine in some settings have fueled a search for more cost-effective alternatives that do not compromise analgesia [1, 6, 2, 7, 8, 9]. A recent study offers new data on a low-cost strategy to address this common issue.
Comparing Local Anesthetic Strategies for TAP Blocks
To address the need for effective, low-cost analgesia in deep inferior epigastric perforator (DIEP) flap reconstruction, the most common form of autologous breast reconstruction, researchers have evaluated a readily available alternative to liposomal bupivacaine. The high cost of the liposomal formulation often limits its use, despite its role in enhanced recovery protocols. This study investigated a strategy of adding dexamethasone, a corticosteroid known to have anti-inflammatory effects and prolong the duration of local anesthetics, to standard bupivacaine. The investigation directly compared the clinical efficacy of this combination (bupivacaine with 1 mg dexamethasone) against commercially available liposomal bupivacaine when used for transversus abdominis plane (TAP) blocks in patients undergoing DIEP flap procedures.
Study Design and Patient Cohorts
This single-institution retrospective study analyzed five years of patient data from 2018 to 2023. The analysis included all patients who received intraoperative, ultrasound-guided transversus abdominis plane (TAP) blocks during their procedure. The primary outcomes measured were length of stay (LOS), total postoperative morphine milligram equivalents (MME), and Numeric Pain Rating Scale scores, with a p-value of less than 0.05 considered statistically significant. The cohort of 178 patients was divided into two groups: Group 1 (95 patients) received commercially available liposomal bupivacaine, and Group 2 (83 patients) received a mixture of 30 mL of 0.25% bupivacaine with 1 mg of dexamethasone. Crucially, the study found no statistically significant differences between the cohorts in baseline characteristics such as age, prevalence of BMI greater than 30 kg/m², smoking status, laterality, perforator selection, or wound complications. This baseline comparability strengthens the conclusion that observed differences in outcomes were likely due to the anesthetic formulation itself.
Improved Early Outcomes with Dexamethasone-Bupivacaine
The study's findings demonstrate that the bupivacaine-dexamethasone combination was associated with superior early postoperative outcomes compared to liposomal bupivacaine. Patients who received bupivacaine with dexamethasone (Group 2) had a significantly shorter mean length of stay at 2.88 days, compared to 3.49 days for the liposomal bupivacaine group (Group 1), a difference that was statistically significant (p<0.001). This group also required substantially less opioid medication. Total postoperative morphine milligram equivalents (MME) averaged 70.6 ± 60.0 in the dexamethasone group, a significant reduction from the 104.7 ± 72.8 MME used in the liposomal bupivacaine group (p<0.001). Furthermore, early pain control was improved; on postoperative day one, patients in Group 2 reported lower mean pain scores (3.44 ± 1.50) than those in Group 1 (4.53 ± 1.57), a statistically significant improvement (p<0.001). This analgesic advantage was concentrated in the early recovery phase, as the researchers noted no significant differences in pain scores on postoperative days 2, 3, or 4.
Clinical Implications for Practice
For clinicians managing patients after deep inferior epigastric perforator (DIEP) flap reconstruction, these findings suggest that adding dexamethasone to bupivacaine for transversus abdominis plane (TAP) blocks is a clinically effective and economically favorable alternative to liposomal bupivacaine. The observed shorter length of stay (2.88 vs 3.49 days; p<0.001) and reduced total opioid consumption (70.6 vs 104.7 MME; p<0.001) represent tangible benefits for both patient recovery and hospital resource utilization. A shorter hospitalization reduces costs and the risk of nosocomial complications, while lower opioid use helps mitigate common side effects like nausea and constipation and supports broader opioid stewardship efforts.
The superior pain control on the first postoperative day is particularly relevant. While the analgesic benefit did not extend through subsequent days, postoperative day one is a critical period where severe pain can impede early mobilization, a key component of enhanced recovery after surgery (ERAS) protocols. By providing better initial pain relief, the bupivacaine-dexamethasone combination may facilitate faster recovery milestones. Therefore, incorporating this simple, low-cost mixture into ERAS protocols could allow institutions to optimize postoperative pain management and accelerate discharge without the significant financial outlay required for liposomal bupivacaine, making it a practical consideration for any practice performing these reconstructions.
References
1. Almeida V, Donato G, Carvalho AAD, et al. Liposomal Bupivacaine in Transversus Abdominis Plane Block for Postoperative Pain Control After Autologous Breast Reconstruction: A Systematic Review and Meta‐Analysis. Microsurgery. 2025. doi:10.1002/micr.70126
2. Ha AY, Keane G, Parikh RP, et al. The Analgesic Effects of Liposomal Bupivacaine versus Bupivacaine Hydrochloride Administered as a Transversus Abdominis Plane Block after Abdominally Based Autologous Microvascular Breast Reconstruction: A Prospective, Single-Blind, Randomized, Controlled Trial. Plastic & Reconstructive Surgery. 2019. doi:10.1097/prs.0000000000005698
3. Cai Q, Gao M, Chen G, Pan L. Transversus Abdominis Plane Block versus Wound Infiltration with Conventional Local Anesthetics in Adult Patients Underwent Surgery: A Systematic Review and Meta‐analysis of Randomized Controlled Trials. BioMed Research International. 2020. doi:10.1155/2020/8914953
4. Abdou SA, Daar D, Wilson SC, Thanik V. Are Transversus Abdominis Plane Blocks the New Standard of Care in Microsurgical Breast Reconstruction? A Systematic Review and Meta-analysis. Plastic and Reconstructive Surgery, Global Open. 2019. doi:10.1097/01.GOX.0000584332.85402.12
5. Alsharari AF, Abuadas FH, Alnassrallah YS, Salihu D. Transversus Abdominis Plane Block as a Strategy for Effective Pain Management in Patients with Pain during Laparoscopic Cholecystectomy: A Systematic Review. Journal of Clinical Medicine. 2022. doi:10.3390/jcm11236896
6. Park RH, Chou J, DeVito RG, et al. Effectiveness of Liposomal Bupivacaine Transversus Abdominis Plane Block in DIEP Flap Breast Reconstruction: A Randomized Controlled Trial. Plastic & Reconstructive Surgery. 2024. doi:10.1097/prs.0000000000011326
7. Kendall MC, Alves LJC, Oliveira GD. Liposome Bupivacaine Compared to Plain Local Anesthetics to Reduce Postsurgical Pain: An Updated Meta-Analysis of Randomized Controlled Trials. Pain Research and Treatment. 2018. doi:10.1155/2018/5710169
8. Jiao B, Xu X, Yan C, Xu J, Chen C. Comparing the analgesic efficacy of liposomal bupivacaine versus bupivacaine for postoperative pain management in breast surgery: protocol for a systematic review and meta-analysis. BMJ Open. 2025. doi:10.1136/bmjopen-2025-108951
9. Nguyen L, Glassman GE, Afshari A, et al. Randomized Controlled Trial Comparing Liposomal to Plain Bupivacaine in the Transversus Abdominis Plane for DIEP Flap Breast Reconstruction. Plastic & Reconstructive Surgery. 2023. doi:10.1097/prs.0000000000010710